N/A N=20 The Effects of Fractional CO2 Laser on Poikiloderma of Civatte
Poikiloderma of Civatte
Primary: Change in Overall Improvement of Poikiloderma of Civatte (POC) From Baseline at 12 Weeks — 11.01; 6.03; 8.51; 5.89 percentage
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=24 Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte
Poikiloderma of Civatte · Dyschromia · Pigmentation Disorders
Primary: Severity Assessment Score — -0.06; 0.2 score on a scale
Phase 4 N=30 Photodynamic Therapy for Papulopustular Rosacea
Rosacea · Papulopustular Rosacea
Primary: Improvement of the Inflammatory Lesions (Papules, Pustules, Nodules), Erythema, and Telangiectasia of Rosacea as Assessed by the Investigator's Global Assessment (IGA)…
Phase 2 N=10 Open Label Pilot Study of Apremilast in Treatment of Rosacea
Erythematotelangiectatic Rosacea · Papulopustular Rosacea
Primary: Change From Baseline in the Total Number of Papulopustular Lesions at Week 12 — -0.2 papule count — p=0.98
N/A N=27 Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
Port Wine Stain
Primary: Change From Baseline in a* and E at 8 Weeks — 1.27; 0.43; 4.08; 2.59 units on a scale
N/A N=10 Dermatosis Papulosa Nigra
Facial Dermatoses · Seborrheic Keratoses
Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance
Phase 2 N=32 Comparison of Metvix Photodynamic Therapy (PDT) With Its Vehicle in the Treatment of Photoaged Skin
Photoaged Skin
Primary: Number of Participants With Severity of Photodamage — 0; 0; 1; 0 Participants
N/A N=29 Study to Assess the Cosmetic Changes in the Facial Skin After Use of a Topical Retinoid Product in Participants With Moderate to Severe Photodamage
Skin Care
Primary: Change From Baseline in Overall Photodamage Score — 5.6; -0.8 score on a scale — p=<0.001
Phase 2 N=24 Effects of PRK 124 Lotion in Acne Rosacea
Acne Rosacea
Primary: Erythema Severity — 44.53 Erythema percent improvement
N/A N=22 Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
Erythematotelangiectatic Rosacea · Papulopustular Rosacea
Primary: Degree of Improvement in Erythematotelangiectatic Rosacea and Papulopustular Rosacea — 2.114; 2.088 score on a scale
Phase 2 N=216 Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
Papulopustular Rosacea
Primary: Co-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory Lesions — -10.0; -6.7; -9.2 lesions (rosacea inflammatory)
Phase 3 N=688 Phase 3 Papulopustular Rosacea Study
Papulopustular Rosacea
Primary: Success Rate — 40.1; 18.8 Percentage of participants — p=<0.001
Phase 3 N=683 Phase 3 Papulopustular Rosacea Study
Papulopustular Rosacea (PPR)
Primary: Success Rate — 38.4; 11.6 Percentage of participants — p=<0.001
N/A N=10 Combination Gel and Vascular ND in Mild to Moderate Rosacea
Rosacea
Primary: IGA of Improvement — 3.1; 3.5 units on a scale
N/A N=7 Photocil (Topical) for the Treatment of Atopic Dermatitis
Atopic Dermatitis
Primary: Number of Pruritus Events in Last 30 Days — 7.4; 1.9 Events
Phase 4 N=30 Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea
Erythematotelangiectatic Rosacea
Primary: Clinical Erythema Assessment (CEA) Score At 6-Month Post-Baseline — 1.6; 2.4 score on a scale
Phase 2 N=20 Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients
Acne Vulgaris
Primary: Photoactive Porphyrins Level — 33.0; 24.8; 19.7 Fluorescence intensity unit
Phase 3 N=449 Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
Rosacea
Primary: Long Term Safety & Efficacy of CD07805/47 Gel 0.5% in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea. — -1.5; -1.4; -1.5; -1.7 scores on a scale
Phase 2 N=20 Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
Acne Vulgaris
Primary: Proportion of Patients With Moderate to Severe Hypopigmentation and Hyperpigmentation Assessed After Treatment — 0; 0 participants
Phase 2 N=10 An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema
Papulopustular Rosacea
Primary: Facial Erythema — 6.6; 6 score on a scale
Phase 3 N=50 An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea
Rosacea · Erythema
Primary: Responder — 16.7 percentage of responders
N/A N=22 Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment
Port-Wine Stain
Primary: Percent Change in Blanching of Port Wine Stain — 6; 5 percentage
N/A N=15 Photocil (Topical) for the Treatment of Vitiligo
Vitiligo
Primary: Percent Repigmentation — 48.5; 2.5 Percent Repigmentation
N/A N=12 Photocil (Topical) for the Treatment of Psoriasis Vulgaris
Psoriasis
Primary: Percent Lesion Clearance — 75.7; 8 Percent Clearance
Phase 2 N=156 Eflornithine and/or Diclofenac in Treating Patients With Sun-Damaged Skin
Other Benign Neoplasm of Skin, Unspecified
Primary: Changes in Putrescine Over 3 Months — 0.03; 1.45; 0.2 nmol/g skin
Phase 3 N=552 Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea
Rosacea
Primary: Proportion of Subjects With Composite Success — 60; 58; 23 Participants
Phase 4 N=20 Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)
Acne Vulgaris · Post Inflammatory Hyperpigmentation
Primary: Percentage of Participants With Improvement in Acne IGA (Investigator Global Assessment) — 92 percentage of participants
Phase 4 N=207 Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea
Papulopustular Rosacea
Primary: Nominal Change From Baseline in Inflammatory Lesion (IL) Count (Sum of Papules and Pustules) at Week 2 (LOCF: Last Observation Carried Forward) — -10.5; -9.4…
Phase 4 N=123 AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
Acne Vulgaris
Primary: Absolute Change From Baseline in Post-Inflammatory Hyperpigmentation (PIH) Overall Disease Severity (ODS) Scores at Week 24 — -2.1; -2.1 score on a scale
N/A N=25 PHNA, Efficacy of Tretinoin Cream on Post-phototherapy Hyperpigmentation
Vitiligo
Primary: The Degree of Hyperpigmentation at 12 Weeks — 56.8; 57.6; 51.0; 54.3 score on a scale — p=0.002